Company Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.
Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Oct 5, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 226 |
| CEO | Dr. David P. Meeker M.D. |
Contact Details
Address: 222 Berkeley Street, 12th Floor Boston, Massachusetts 02116 United States | |
| Phone | 857-264-4280 |
| Website | rhythmtx.com |
Stock Details
| Ticker Symbol | RYTM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001649904 |
| CUSIP Number | 76243J105 |
| ISIN Number | US76243J1051 |
| Employer ID | 46-2159271 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David P. Meeker M.D. | Chairman, President and Chief Executive Officer |
| Hunter C. Smith M.B.A. | Chief Financial Officer and Treasurer |
| Joseph Shulman | Chief Technical Officer |
| Yann Mazabraud | Executive Vice President and Head of International |
| Jennifer Lee | Executive Vice President and Head of North America |
| Christopher German | Corporate Controller, Principal Accounting Officer and Executive Director |
| David Connolly | Head of Investor Relations and Corporate Communications |
| Jim Flaherty | Senior Vice President and General Counsel |
| Sarah Ryan | Vice President of Sales and Marketing |
| Pamela J. Cramer | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 17, 2024 | 8-K | Current Report |
| May 9, 2024 | 144 | Filing |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 30, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |